Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) EBT: 2023-2025

Historic EBT for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.0 million.

  • Mereo BioPharma Group's EBT rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 9.32%. This contributed to the annual value of -$43.3 million for FY2024, which is 44.19% down from last year.
  • Mereo BioPharma Group's EBT amounted to -$7.0 million in Q3 2025, which was up 51.94% from -$14.6 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year EBT high stood at -$1.8 million for Q2 2023, and its period low was -$15.0 million during Q3 2024.
  • Its 3-year average for EBT is -$9.8 million, with a median of -$9.6 million in 2023.
  • Its EBT has fluctuated over the past 5 years, first slumped by 599.89% in 2024, then spiked by 53.18% in 2025.
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's EBT stood at -$9.6 million in 2023, then climbed by 26.92% to -$7.0 million in 2024, then spiked by 53.18% to -$7.0 million in 2025.
  • Its last three reported values are -$7.0 million in Q3 2025, -$14.6 million for Q2 2025, and -$12.9 million during Q1 2025.